Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Company Deals

AstraZeneca Expands China Presence with Over 30 Agreements at CIIE

Fineline Cube Nov 8, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...

Company

Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai

Fineline Cube Nov 8, 2023

S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...

Company Deals

Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China

Fineline Cube Nov 8, 2023

Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...

Company Deals

Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China

Fineline Cube Nov 8, 2023

Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai...

Company Deals

Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China

Fineline Cube Nov 8, 2023

Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...

Company Drug

Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012

Fineline Cube Nov 8, 2023

Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Deals Medical Device

Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology

Fineline Cube Nov 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...

Policy / Regulatory

9th National Volume-Based Procurement Round Results in 70% Price Reduction for 41 Drugs

Fineline Cube Nov 7, 2023

The results of the 9th round of China’s national volume-based procurement (VBP) program have been...

Company Deals

Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital

Fineline Cube Nov 7, 2023

Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in...

Company Drug

Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial

Fineline Cube Nov 7, 2023

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...

Company

FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results

Fineline Cube Nov 7, 2023

US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...

Company Deals

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

Fineline Cube Nov 7, 2023

GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...

Company Drug

Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy

Fineline Cube Nov 7, 2023

Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...

Company Drug

Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil

Fineline Cube Nov 7, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...

Company Deals

WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares

Fineline Cube Nov 7, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial

Fineline Cube Nov 7, 2023

Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...

Company Deals Hospital Medical Device

Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery

Fineline Cube Nov 7, 2023

China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic...

Company

Danone Enters China’s Adult FSMP Market with Local Production of Fortimel

Fineline Cube Nov 7, 2023

France-based food company Danone has revealed its strategic plans to enter the adult foods for...

Company Deals

SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China

Fineline Cube Nov 7, 2023

China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...

Company Drug

RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002

Fineline Cube Nov 7, 2023

RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...

Posts pagination

1 … 409 410 411 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.